<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392286</url>
  </required_header>
  <id_info>
    <org_study_id>1501015143</org_study_id>
    <nct_id>NCT02392286</nct_id>
  </id_info>
  <brief_title>Corticosteroid Dosage for Crohn's Disease Flare</brief_title>
  <official_title>A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized comparative effectiveness trial designed to compare fixed dosing and
      weight-based dosing of corticosteroids in patients with Crohn's disease flares.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Determine if weight-based corticosteroid (1mg/kg daily) induces remission at a greater
           rate than fixed corticosteroid dosage.

        -  Determine if weight-based corticosteroid is associated with greater rate of adverse
           events than fixed corticosteroid dosage.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">December 19, 2016</completion_date>
  <primary_completion_date type="Actual">December 19, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants in Remission at End of 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with Harvey Bradshaw Index &lt; 5 at end of 2 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response at End of 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with at least a 3-point drop in Harvey-Bradshaw Index at end of 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response or Remission at End of 1 Week</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 1 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response or Remission at End of 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response or Remission at End of 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Corticosteroid-associated Side Effects</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with side effects that may be associated with use of corticosteroids such as mood swings, sleep disturbance, edema, acne, bruising, myalgias.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Weight-based</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
    <arm_group_label>Fixed dose</arm_group_label>
    <arm_group_label>Weight-based</arm_group_label>
    <other_name>Prednisone</other_name>
    <other_name>Methylprednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18

          -  Established diagnosis of Crohn's disease

          -  Diagnosis of Crohn's flare

          -  Decision by treating gastroenterologist to start corticosteroid therapy

        Exclusion Criteria:

          -  Patients in whom corticosteroid therapy is contraindicated: immunocompromised (active
             cancer on chemotherapy or radiation treatment), severe liver disease (decompensated
             cirrhosis, active alcoholic hepatitis), end-stage renal disease on dialysis, AIDS or
             AIDS-defining illness; myocardial infarction within the past year; NYHA Class 4 heart
             failure

          -  Patients on systemic corticosteroid therapy currently or within the past 8 weeks

          -  Patients not on stable doses of immunomodulators or biologics for at least 8 weeks

          -  Infectious colitis (e.g., C. difficile, CMV, HSV)

          -  Systemic infections (bacteremia, fungal infections)

          -  Fulminant Crohn's disease

          -  Patients who require imminent surgery

          -  Abscess

          -  Pregnancy

          -  Weight &lt;35 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loren Laine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University, Section of Digestive Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <results_first_submitted>December 23, 2019</results_first_submitted>
  <results_first_submitted_qc>January 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Weight-based</title>
          <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
        </group>
        <group group_id="P2">
          <title>Fixed Dose</title>
          <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Weight-based</title>
          <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
        </group>
        <group group_id="B2">
          <title>Fixed Dose</title>
          <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants in Remission at End of 2 Weeks</title>
        <description>Number of participants with Harvey Bradshaw Index &lt; 5 at end of 2 weeks</description>
        <time_frame>2 weeks</time_frame>
        <population>1 patient in fixed dose group did not return for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Weight-based</title>
            <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose</title>
            <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Remission at End of 2 Weeks</title>
          <description>Number of participants with Harvey Bradshaw Index &lt; 5 at end of 2 weeks</description>
          <population>1 patient in fixed dose group did not return for this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response at End of 2 Weeks</title>
        <description>Number of participants with at least a 3-point drop in Harvey-Bradshaw Index at end of 2 weeks</description>
        <time_frame>2 weeks</time_frame>
        <population>1 patient in fixed-dose group did not return for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Weight-based</title>
            <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose</title>
            <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response at End of 2 Weeks</title>
          <description>Number of participants with at least a 3-point drop in Harvey-Bradshaw Index at end of 2 weeks</description>
          <population>1 patient in fixed-dose group did not return for this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response or Remission at End of 1 Week</title>
        <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 1 week</description>
        <time_frame>1 week</time_frame>
        <population>1 patient in weight-based group and 2 patients in fixed-dose group did not return for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Weight-based</title>
            <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose</title>
            <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response or Remission at End of 1 Week</title>
          <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 1 week</description>
          <population>1 patient in weight-based group and 2 patients in fixed-dose group did not return for this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response or Remission at End of 4 Weeks</title>
        <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 4 weeks</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients in weight-based group and 1 patient in fixed-dose group did not return for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Weight-based</title>
            <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose</title>
            <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response or Remission at End of 4 Weeks</title>
          <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 4 weeks</description>
          <population>2 patients in weight-based group and 1 patient in fixed-dose group did not return for this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response or Remission at End of 12 Weeks</title>
        <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <population>1 patient in fixed-dose group did not return for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Weight-based</title>
            <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose</title>
            <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response or Remission at End of 12 Weeks</title>
          <description>Number of participants with Harvey-Bradshaw Index &lt;5 or with a drop in Harvey-Bradshaw Index of at least 3 points at end of 12 weeks</description>
          <population>1 patient in fixed-dose group did not return for this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Corticosteroid-associated Side Effects</title>
        <description>Number of participants with side effects that may be associated with use of corticosteroids such as mood swings, sleep disturbance, edema, acne, bruising, myalgias.</description>
        <time_frame>12 weeks</time_frame>
        <population>1 patient in fixed dose did not return and did not have any assessment for this outcome after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Weight-based</title>
            <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose</title>
            <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Corticosteroid-associated Side Effects</title>
          <description>Number of participants with side effects that may be associated with use of corticosteroids such as mood swings, sleep disturbance, edema, acne, bruising, myalgias.</description>
          <population>1 patient in fixed dose did not return and did not have any assessment for this outcome after randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Weight-based</title>
          <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
        </group>
        <group group_id="E2">
          <title>Fixed Dose</title>
          <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
Corticosteroid: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Loren Laine</name_or_title>
      <organization>Yale</organization>
      <phone>203-785-7312</phone>
      <email>loren.laine@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

